Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors

Por Ahamadi, M, Freshwater, T, Prohn, M, Li, CH, de Alwis, DP, de Greef, R, Elassaiss‐Schaap, J, Kondic, A, Stone, JA
Publicado no CPT Pharmacometrics Syst Pharmacol (2016)

Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma

Por de Greef, R, Elassaiss‐Schaap, J, Chatterjee, M, Turner, DC, Ahamadi, M, Forman, M, Cutler, D, de Alwis, DP, Kondic, A, Stone, J
Publicado no CPT Pharmacometrics Syst Pharmacol (2016)

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Por Chatterjee, M., Turner, D. C., Felip, E., Lena, H., Cappuzzo, F., Horn, L., Garon, E. B., Hui, R., Arkenau, H.-T., Gubens, M. A., Hellmann, M. D., Dong, D., Li, C., Mayawala, K., Freshwater, T., Ahamadi, M., Stone, J., Lubiniecki, G. M., Zhang, J., Im, E., De Alwis, D. P., Kondic, A. G., Fløtten, Ø.
Publicado no Ann Oncol (2016)